CA2209557A1 - Interferent chimiquement modifie - Google Patents

Interferent chimiquement modifie

Info

Publication number
CA2209557A1
CA2209557A1 CA002209557A CA2209557A CA2209557A1 CA 2209557 A1 CA2209557 A1 CA 2209557A1 CA 002209557 A CA002209557 A CA 002209557A CA 2209557 A CA2209557 A CA 2209557A CA 2209557 A1 CA2209557 A1 CA 2209557A1
Authority
CA
Canada
Prior art keywords
ifn
con
chemically modified
interferon
glycosyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002209557A
Other languages
English (en)
Inventor
David S. Collins
Jennifer Lin-Chun Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2209557A1 publication Critical patent/CA2209557A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention se rapporte à un interférent de consensus chimiquement modifié possédant au moins un ligand glycosyle, ce ou ces ligands glycosyles étant conjugués à l'interférent de consensus. Des compositions pharmaceutiques contenant cet analogue et des procédés de traitement utilisant les compositions de l'invention sont également décrits.
CA002209557A 1995-01-13 1996-01-11 Interferent chimiquement modifie Abandoned CA2209557A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37247895A 1995-01-13 1995-01-13
US08/372,478 1995-01-13

Publications (1)

Publication Number Publication Date
CA2209557A1 true CA2209557A1 (fr) 1996-07-18

Family

ID=23468282

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002209557A Abandoned CA2209557A1 (fr) 1995-01-13 1996-01-11 Interferent chimiquement modifie

Country Status (9)

Country Link
EP (1) EP0804248A2 (fr)
JP (1) JPH10513440A (fr)
KR (1) KR19980701814A (fr)
AU (1) AU4751896A (fr)
BR (1) BR9607599A (fr)
CA (1) CA2209557A1 (fr)
IL (1) IL116730A0 (fr)
WO (1) WO1996021468A2 (fr)
ZA (1) ZA96206B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292273A3 (fr) * 2001-10-10 2011-11-23 BioGeneriX AG Remodelage et Glycoconjugaison de Peptides
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2005012484A2 (fr) 2003-07-25 2005-02-10 Neose Technologies, Inc. Conjugues anticorps-toxines
WO2005037214A2 (fr) 2003-10-14 2005-04-28 Intermune, Inc. Acylsulfonamides et acides carboxyliques macrocycliques utilises en tant qu'inhibiteurs de la replication du virus de l'hepatite c
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP1814573B1 (fr) 2004-10-29 2016-03-09 ratiopharm GmbH Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf)
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
EP2305696A3 (fr) 2005-07-25 2011-10-12 Intermune, Inc. Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C
EA200801050A1 (ru) 2005-10-11 2008-12-30 Интермьюн, Инк. Соединения и способы ингибирования репликации вирусного гепатита с
AR078117A1 (es) 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
US20120123338A1 (en) 2010-06-16 2012-05-17 Medtronic, Inc. Damping systems for stabilizing medications in drug delivery devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
KR950014915B1 (ko) * 1991-06-19 1995-12-18 주식회사녹십자 탈시알로당단백-포함화합물
TW263437B (fr) * 1992-09-24 1995-11-21 Takeda Pharm Industry Co Ltd
CN1087093A (zh) * 1993-09-16 1994-05-25 华西医科大学药学院 肝靶向性的半乳糖基干扰素偶联物

Also Published As

Publication number Publication date
AU4751896A (en) 1996-07-31
BR9607599A (pt) 1998-06-09
KR19980701814A (ko) 1998-06-25
MX9705119A (es) 1997-10-31
WO1996021468A2 (fr) 1996-07-18
JPH10513440A (ja) 1998-12-22
IL116730A0 (en) 1996-05-14
ZA96206B (en) 1996-08-19
WO1996021468A3 (fr) 1996-09-12
EP0804248A2 (fr) 1997-11-05

Similar Documents

Publication Publication Date Title
EP2599503B1 (fr) Conjugués de polymère d'interféron bêta-1A et leurs utilisations
US5372808A (en) Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
JPH1067800A (ja) インターフェロン複合体
AU4751896A (en) Chemically modified interferon
EP0643972B1 (fr) Utilisation d'un facteur-1 stimulant de colonie (CSF-1) recombinant pour la préparation d'un médicament traitant l'infection par le cytomégalovirus
AU660633B2 (en) Methods and compositions for the treatment of cell proliferation disorders
JP2006519235A (ja) ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
KR20100063108A (ko) 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
CA2106821A1 (fr) Cytokines glycosylees
CN101448525A (zh) 聚乙二醇-干扰素α缀合物
MXPA97005119A (en) Modified interferone quimicame
EP2048158B1 (fr) Mutéines de l'interferon alpha humain glycosylees et leur procédé d'obtention et d'utilisation
CN1178554A (zh) 化学修饰的干扰素
HK1131345A (en) Polyethylene glycol-interferon alpha conjugate
HK1181645B (en) Polymer conjugates of interferon beta-1a and uses thereof
HK1089393B (en) Polyalkylene glycol conjugates of interferon beta-1a and uses thereof
HK1150963B (en) Polymer conjugates of interferon beta-1a and uses thereof
KR20070110162A (ko) 폴리에틸렌 글리콜-인터페론 알파 접합체
HK1010340B (en) The manufacture of compositions for the treatment of cell proliferation disorders

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued